Immunotherapy with chemo and radiation for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have newly diagnosed nasopharyngeal cancer that has not been treated before.
- Your cancer is stage II or III according to the AJCC system (spread to lymph nodes but not to other organs).
- You are in good general health (able to care for yourself, with normal blood and organ function).
- You are not pregnant, not breastfeeding, and willing to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immune-based drugs (sintilimab and bevacizumab) plus standard chemotherapy for people with high-risk, locally advanced nasopharyngeal cancer that has spread to lymph nodes. The goal is to see if this approach works better than current treatments.
This trial tests whether adding chemotherapy to a combination of immunotherapy and radiation is more effective than immunotherapy and radiation alone for advanced nasopharyngeal cancer. It is for people whose cancer has not spread to distant organs.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This trial tests whether combining an immunotherapy drug (PD-1 inhibitor) with chemotherapy and radiation can help treat nasopharyngeal cancer that has spread to the lungs. It is for people whose cancer returned more than six months after initial treatment and who haven't had immunotherapy before.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.